[
  {
    "ts": "2025-10-18T14:35:00+00:00",
    "headline": "KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer",
    "summary": "RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during",
    "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-chemotherapy-without-143500308.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "a30a465c-ed23-3e2a-803e-f00ffc471697",
      "content": {
        "id": "a30a465c-ed23-3e2a-803e-f00ffc471697",
        "contentType": "STORY",
        "title": "KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer",
        "description": "",
        "summary": "RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during",
        "pubDate": "2025-10-18T14:35:00Z",
        "displayTime": "2025-10-18T14:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/55f0efacfc9c2ab36a461db1272ce7fa",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J6OqdJxTBkkJ_k0jpoVdQA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/55f0efacfc9c2ab36a461db1272ce7fa.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hAC2njVnkVSi8CFAJH9x1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/55f0efacfc9c2ab36a461db1272ce7fa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-chemotherapy-without-143500308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-chemotherapy-without-143500308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-18T14:30:40+00:00",
    "headline": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients",
    "summary": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.",
    "url": "https://www.investors.com/news/technology/bladder-cancer-padcev-keytruda-merck-pfizer-astellas/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "fc57e9fe-46ee-3e3d-9136-49fc2f129aaf",
      "content": {
        "id": "fc57e9fe-46ee-3e3d-9136-49fc2f129aaf",
        "contentType": "STORY",
        "title": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients",
        "description": "",
        "summary": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.",
        "pubDate": "2025-10-18T14:30:40Z",
        "displayTime": "2025-10-18T14:30:40Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/fc57e9fe-46ee-3e3d-9136-49fc2f129aaf/pfizer-merck-and-astellas.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/cc1ba840394999bd8d2f9e90faab7a81",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xSQ8YwM67Zr8eoVxIL10wg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/cc1ba840394999bd8d2f9e90faab7a81.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/inbcP9SXCOD3CuYclH_fcg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/cc1ba840394999bd8d2f9e90faab7a81.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/bladder-cancer-padcev-keytruda-merck-pfizer-astellas/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-18T14:30:00+00:00",
    "headline": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
    "summary": "RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible f",
    "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-143000805.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "09153f5c-7d4f-326d-9d97-7c02f5e10489",
      "content": {
        "id": "09153f5c-7d4f-326d-9d97-7c02f5e10489",
        "contentType": "STORY",
        "title": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
        "description": "",
        "summary": "RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible f",
        "pubDate": "2025-10-18T14:30:00Z",
        "displayTime": "2025-10-18T14:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/eaaad3561b77f5ae63a4635f2cf404cc",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oxkYgCKceCexTdPGho39bQ--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/eaaad3561b77f5ae63a4635f2cf404cc.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NHEtUnVMljgWqLCS7kth_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/eaaad3561b77f5ae63a4635f2cf404cc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-143000805.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-143000805.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-18T10:00:00+00:00",
    "headline": "KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen",
    "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 18, 2025--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma",
    "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-100000876.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "ffba0d8c-f36f-3430-89c5-39d323e6afe1",
      "content": {
        "id": "ffba0d8c-f36f-3430-89c5-39d323e6afe1",
        "contentType": "STORY",
        "title": "KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen",
        "description": "",
        "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 18, 2025--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma",
        "pubDate": "2025-10-18T10:00:00Z",
        "displayTime": "2025-10-18T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/6668846d66178c34e9d9cdea2e0cddf7",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y4oKZrvAfeFI_B14OW3cVg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6668846d66178c34e9d9cdea2e0cddf7.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gyx6Yld4qY5aikjAgrpuNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6668846d66178c34e9d9cdea2e0cddf7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-100000876.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-100000876.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "4523.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]